“Under the shadow of an Omicron catastrophe, the ever-evolving mutant(s) have adversely affected the vaccines and monoclonal antibody therapies substantially that were based upon immunity against the wild type virus. At the same time, mutant-based vaccines, due to manufacture and regulatory hurdles as well as the complex global distribution of different viral strains, will not be able to catch up in the real world.

                                              Emil Tsai, MD, PhD, CEO